Tech Company Financing Transactions
Zogenix Funding Round
Chicago Growth Partners participated in a $20 million Series B capital raise for Zogenix. The round closed on 12/7/2009.
Transaction Overview
Company Name
Announced On
12/7/2009
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Chicago Growth Partners (Arda Minocherhomjee)
Proceeds Purpose
The capital primarily will be used to fully support the launch of SUMAVEL(TM) DosePro(TM) (sumatriptan injection) needle-free delivery system, the company's first product, that will launch in January 2010. Zogenix is also advancing its product pipeline and is actively engaged in efforts to out-license the unique, needle-free DosePro technology to other biopharmaceutical companies.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 455
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Website
Email Address
Overview
Zogenix (NASDAQ: ZGNX) is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Farr
Chief Financial Officer
Michael Smith
Chief Medical Officer
Bradley Galer
VP - Bus. Development
Gail Farfel
VP - Bus. Development
Ashish Sagrolikar
Browse more venture capital transactions:
Prev: 12/7/2009: Trazzler venture capital transaction
Next: 12/7/2009: ElectronDB venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs